Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Teva, Regeneron enter deal potentially worth up to $2.6 billion to develop pain therapy fasinumab
Teva, Regeneron enter deal potentially worth up to $2.6 billion to develop pain therapy fasinumab
Teva, Regeneron enter deal potentially worth up to $2.6 billion to develop pain therapy fasinumab
Submitted by
admin
on September 20, 2016 - 11:11am
Source:
First Word Pharma
News Tags:
Teva Pharmaceutical
Regeneron
fasinumab
painkillers
Headline:
Teva, Regeneron enter deal potentially worth up to $2.6 billion to develop pain therapy fasinumab
Do Not Allow Advertisers to Use My Personal information
